Compounds / Tissue Repair / Ara-290

Ara-290

Ara-290 (Cibinetide — Innate Repair Receptor Agonist, Helix-B EPO Peptide)

Tissue RepairEmerging ResearchFDA: Not approved; clinical trials ongoing

Overview

Clinical trials: benefits for diabetic peripheral neuropathy and sarcoidosis-related small-fiber neuropathy. No hematopoietic effects at study doses. Clinical development ongoing.

Mechanism of Action

11-AA non-erythropoietic peptide from erythropoietin helix-B domain. Selectively activates innate repair receptor (EPOR/CD131 heterodimer). Anti-inflammatory and tissue-protective without red blood cell stimulation (no hematopoietic effect).

Molecular Profile

Molecular weight

~1388 Da

Key Research Findings

Non-erythropoietic EPO analog; peripheral nerve regeneration; diabetic neuropathy; sarcoidosis neuropathy; anti-inflammatory.

Published Research

PNAS (2015)

Brines M et al. Cibinetide is neuroprotective in diabetic peripheral neuropathy

View source

Related Tissue Repair Compounds

BPC-157 TB-500 AHK-Cu KPV MGF PEG-MGF

Clinical Guidance

Research data is not a treatment plan. If you are considering Ara-290, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.

Running Ara-290? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator · Full deep dive · Peptide fundamentals